All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Fox Chase Cancer Center’s Dr. Richard Bleicher Speaks at MD Anderson Breast Cancer Fellowship Program Commencement

July 25th 2024

Richard Bleicher, MD, FACS, has been named 2023-2024 University of Texas MD Anderson Cancer Center Breast Surgical Oncology Fellowship’s Annual Distinguished Commencement Visiting Professor.

Dostarlimab Wins Full Approval in Canada for dMMR/MSI-H Endometrial Cancer

July 25th 2024

Health Canada has granted full approval to dostarlimab monotherapy for patients with recurrent or advanced dMMR/MSI-H endometrial cancer.

Fecal Microbiota Transplants May Enhance Immunotherapy Efficacy in GI Cancers

July 25th 2024

Donor fecal microbiota transplants increased the activity of immunotherapy in patients with GI cancers.

Bintrafusp Alfa Induces Responses in Post-Platinum Metastatic Cervical Cancer

July 25th 2024

Bintrafusp alfa elicited responses in patients with recurrent/metastatic cervical cancer, warranting further exploration of TGF-β-targeted therapies.

FDA Accepts Resubmission of BLA for Cosibelimab in Locally Advanced or Metastatic CSCC

July 25th 2024

The FDA has accepted the resubmission of a BLA for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Time-Limited Acalabrutinib/Obinutuzumab Produces Durable Responses in Treatment-Naive CLL

July 25th 2024

Time-limited acalabrutinib plus obinutuzumab produced responses in treatment-naive chronic lymphocytic leukemia.

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

July 25th 2024

Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

July 24th 2024

Blinatumomab added to consolidation chemotherapy led to a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer

July 24th 2024

Paolo Tarantino, MD, discusses questions about the optimal sequencing of antibody-drug conjugates in endocrine-refractory, HR-positive breast cancer.

Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer

July 24th 2024

Shubham Pant, MD, MBBS, discusses findings from the phase 2b HERIZON-BTC-01 study of zanidatamab in pretreated HER2-positive biliary tract cancer.

RAS-Directed Therapy and Patient Selection Are Sectors to Watch in Pancreatic Cancer

July 24th 2024

Eileen M. O'Reilly, MD, details how RAS-directed therapy could potentially change the pancreatic cancer landscape and highlights updated data in the space.

FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer

July 24th 2024

The FDA has accepted the new drug application for the new TLX007-CDx cold kit for the preparation of PSMA-PET imaging in patients with prostate cancer.

Northwell, The START Center for Cancer Research to Form Strategic Partnership

July 24th 2024

New START early-phase clinical trial site brings advanced cancer research to Northwell’s Cancer Institute, increases patient access

Reduced Incidence of ICANS and CRS After 2 Weeks Post-CAR T Supports Shortened Monitoring Period in DLBCL

July 24th 2024

The incidence of ICANS and CRS post-CAR T-cell therapy decreased after 2 weeks in patients with DLBCL, supporting a reduction of the monitoring period.

Novel Prompt Shows Potential to Decrease Overtreatment in Older Patients With Early-Stage Breast Cancer

July 24th 2024

An EHR-based prompt or “nudge” decreased the rates of sentinel lymph node biopsy among older patients with early-stage breast cancer.

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line

July 24th 2024

Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy

July 23rd 2024

Crofelemer did not improve the incidence of diarrhea in patients with solid tumors receiving targeted therapy.

Study Shows Real-World Benefit of Rituximab Maintenance After Frontline BR in Mantle Cell Lymphoma

July 23rd 2024

Rituximab maintenance therapy following frontline bendamustine plus rituximab improved EFS, EFS2, and OS vs no maintenance therapy in patients with MCL.

Landmark Study Shows Elevated Cancer Risk For Women With Endometriosis

July 23rd 2024

Women with severe endometriosis are 10 times more likely to get ovarian cancer, compared to women who do not have the disease.

Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia

July 23rd 2024

Iopofosine I 131 generated a major response rate of 56.4% in patients with relapsed/refractory Waldenström macroglobulinemia.